Richter’s Biosimilar Costs ‘Took Up A Lot Of Resources Last Year’

Growth For Teriparatide Biosimilar Terrosa Expected To Slow In 2022

 
• By Dean Rudge
  
Watering_Plant
Richter praised its licensing deal with Hikma • Source: Shutterstock

More from Biosimilars

More from Products